-
2023-509171-16-00
5
2020-11-23
Classic Congenital Adrenal Hyperplasia (CAH)
-
2024-514404-13-00
5
2020-10-01
Atopic Dermatitis
-
2023-504998-20-00
5
2020-09-18
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2024-514079-17-00
10
2020-05-28
Endogenous Cushing Syndrome
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501012-34-00
5
2020-02-27
Pulmonary Arterial Hypertension
-
2024-515156-21-00
5
2020-01-09
Ulcerative Colitis
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2023-507405-34-00
5
2019-08-07
First-line patients with advanced biliary tract cancers (BTC)
-
2022-502498-40-00
5
2019-07-26
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2023-505478-14-00
5
2019-05-09
Psoriatic Arthritis
-
2023-506827-26-00
5
2019-05-02
While it is well-established that long-term good glycaemic control wil
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2024-513912-89-00
10
2018-12-13
Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofibrosis (MF) Wit
-
2024-510976-19-00
5
2018-11-30
Patients with Unresectable Locally Advanced or Metastatic Urothelial C
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2022-501017-31-00
5
2016-05-10
Rheumatoid arthritis
-
2025-521503-43-00
4
2026-02-12
Atopic dermatitis
-
2024-512313-41-00
5
2025-05-19
Stable Angina Pectoris
-
2024-512497-10-00
5
2025-09-16
Moderate to Severe Plaque Psoriasis
-
2023-507705-34-00
5
2025-08-29
Moderate to Severe Active Ulcerative Colitis